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Learning objectives
Upon completion of this activity, participants should be 
able to: 
1 Identify the primary mechanism leading to 
tendinopathy.
2 Describe the prevalence of soft-tissue injury and 
tendinopathy in the United Kingdom.
3 Describe repair mechanisms after tendon injury.
4 List key elements of the extracellular matrix in 
tendon.
5 Describe the evidence for the efficacy of newer 
treatments for tendinopathy.
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INTRODUCTION
Soft-tissue disorders are the third most common 
rheumatologic condition in the UK, with 
a reported prevalence of 18 cases per 1,000 
people.1 These disorders, which primarily affect 
tendon, are the main reasons for a musculo-
skeletal consultation with a general practitioner, 
and comprised 30% of all such consultations in a 
1-year study.2 This is probably an under estimate 
of the scale of the problem, because only 40% of 
elderly individuals (over 70 years of age) with 
shoulder pain seek treatment.3 Although many 
soft-tissue problems are treated by a general prac-
titioner, often with NSAIDs, cortico steroid injec-
tion or physiotherapy, a substantial proportion of 
new patient consultations with rheumatologists 
Chronic tendon pathology (tendinopathy), although common, is difficult 
to treat. Tendons possess a highly organized fibrillar matrix, consisting 
of type I collagen and various ‘minor’ collagens, proteoglycans and 
glycoproteins. The tendon matrix is maintained by the resident tenocytes, 
and there is evidence of a continuous process of matrix remodeling, 
although the rate of turnover varies at different sites. A change in 
remodeling activity is associated with the onset of tendinopathy. Major 
molecular changes include increased expression of type III collagen, 
fibronectin, tenascin C, aggrecan and biglycan. These changes are 
consistent with repair, but they might also be an adaptive response 
to changes in mechanical loading. Repeated minor strain is thought to 
be the major precipitating factor in tendinopathy, although further 
work is required to determine whether it is mechanical overstimulation 
or understimulation that leads to the change in tenocyte activity. 
Metalloproteinase enzymes have an important role in the tendon matrix, 
being responsible for the degradation of collagen and proteoglycan in 
both healthy patients and those with disease. Metalloproteinases that show 
increased expression in painful tendinopathy include ADAM 
(a disintegrin and metalloproteinase)-12 and MMP (matrix 
metalloproteinase)-23. The role of these enzymes in tendon pathology 
is unknown, and further work is required to identify novel and specific 
molecular targets for therapy.
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are for soft-tissue rheumatism. Secondary 
referral rates vary widely, but one study reported 
that 17% of new patients seen in a rheumatology 
clinic had soft-tissue complaints.4
Conditions affecting tendons, which 
include chronic pain and rupture, are now 
generally referred to as ‘tendinopathies’ 
in preference to terms such as ‘tendinosis’ 
and ‘tendinitis’, because this terminology 
makes no assumptions about the underlying 
pathology. Although the role of inflamma-
tion is still debated, it has long been known 
that tendino pathies are primarily degenera-
tive conditions—there is usually an absence 
of inflammatory cells in or around the lesion.5 
Consequently, it should be no surprise that 
treatment with anti-inflammatory drugs 
showed little benefit in controlled trials.6 In 
fact, there is remarkably little evidence that 
any conventional therapies are effective.7 It 
has taken several years for research interest to 
grow, but the molecular mechanisms under-
lying the cause and progression of tendino-
pathy are beginning to be elucidated. This 
article will review the molecular pathology of 
tendon, and discuss how this knowledge might 
provide potential new targets for the treatment 
of chronic tendino pathies.
MOLECULAR COMPOSITION OF TENDON
The main principles of tendon structure and 
composition are shown schematically in Figure 1, 
and have been reviewed elsewhere.8,9 Key 
elements of the extracellular matrix are the dense, 
fibrillar network of predominantly parallel-
aligned collagen fibers, principally consisting of 
type I collagen but also containing lesser amounts 
of various ‘minor’ collagens, several proteoglycans 
and a growing list of glyco proteins.8 Although the 
role and function of many of these components 
are still poorly defined, the molecular architecture 
of the matrix is ideally suited primarily for the 
transmission of tensile load; however, tendons 
also function to stabilize joints and absorb large 
shocks, protecting muscles from damage.
There are variations in structure and compo-
sition within a tendon, particularly at the 
myotendinous junction and bone insertion sites 
(enthesis) but also at sites where the tendon is 
compressed, passes through soft-tissue pulleys, 
abuts against ligaments or traverses bony prom-
inences.9 Fibrocartilaginous regions are formed 
in tendons in response to compressive load or 
shear, an adaptive response that protects the 
tendon from damage. The molecular architec-
ture of tendon fibrocartilage has been extensively 
studied, demonstrating increased expres-
sion of molecules normally asso ciated with 
articular cartilage, including type II collagen 
and aggrecan.9
CELL POPULATIONS OF TENDON
The fibroblast-like cells that populate tendon 
are known as ‘tenocytes’, which are thought to 
be distinct from other connective tissue cells, 
although there are currently no specific molec-
ular markers that can be used to character ize 
them.10 There are a variety of cell phenotypes 
described in histologic studies of tendon, 
with more rounded ‘fibrochondrocyte’ cells 
in fibrocartilaginous regions, often arranged in 
columns at the insertion, compared with elon-
gated and dispersed fibroblasts within fibers in 
the tensile-load-bearing regions of the tendon 
mids ubstance.11 There are synovial-like cells in 
the endotenon and epitenon, the thin layers of 
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Figure 1 Schematic of tendon structure and composition. The tendon 
midsubstance (A) is a dense, fibrous connective tissue of crimped fiber 
bundles, mostly aligned with the long axis of the tendon. The matrix consists 
predominantly of type I collagen, with lesser amounts of ‘minor’ collagens, 
proteoglycans and other glycoproteins. The tendon−bone insertion (enthesis) 
(B) shows more rounded cells with an Indian-file appearance and a gradual 
transition from tendon (T) to fibrocartilage (F) to calcified fibrocartilage 
(C) to mineralized bone (M). The matrix composition of the enthesis is 
similar to the tendon midsubstance but also contains additional ‘minor’ 
collagens and increased quantities of the proteoglycans aggrecan and 
biglycan. Photomicrographs (A) and (B) are H&E-stained sections of tendon 
midsubstance and insertion, respectively. Abbreviations: COMP, cartilage 
oligomeric matrix protein; dw, dry weight; H&E, hematoxylin and eosin.
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loose connective tissue that surround the fiber 
bundles or fascicles.12 The different cell popula-
tions have distinct activities in matrix synthesis, 
and are responsive to cytoskeleton-mediated 
matrix interactions and changes in their mechan-
ical environment.12–14 Additional cells include 
smooth muscle and endothelial cells associated 
with blood vessels, which can be found passing 
through the endotenon and epitenon. Fine nerve 
processes and nerve endings are sparse but also 
present, usually in proximity to the blood vessels, 
which are more abundant in the epitenon and 
enveloping paratenon.15
After tendon injury, most repair activity is 
associated with cells from the epitenon and endo-
tenon, which migrate to the lesion and synthe-
size new matrix.16 A proportion of these cells is 
thought to be derived from a resident popula-
tion of stem cells, which can differentiate into a 
variety of mesenchymal tissues, such as bone, fat 
and cartilage, in addition to tendon.10
TENDON MATRIX ADAPTATION AND 
REMODELING
In addition to internal variations within tendon, 
there are variations in structure, composition and 
cell phenotype between tendons from different 
sites, and, increasingly, it is recognized that 
tendons are ‘engineered’ according to the func-
tional demands on them in specific anatomic 
locations.17 There are variations in the content of 
proteoglycan and collagen, and there is evidence 
of different rates of matrix turnover. Highly 
stressed tendons, such as the supraspinatus in 
the rotator cuff, show increased levels of collagen 
remodeling compared with those that are not 
under high stress, for example the distal biceps 
tendon in the forearm, which has much lower 
rates of collagen turnover.18,19 The continual 
process of matrix remodeling is a constitutive 
(albeit slow) activity in normal tendons, affecting 
proteoglycans in addition to collagen,20,21 and 
is thought to be primarily mediated by metallo-
proteinases acting in the extracellular environ-
ment, such as matrix metalloproteinases (MMPs) 
and a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS).
MMPs and ADAMTS have been reviewed 
elsewhere.22,23 Briefly, there are 23 MMPs in 
humans, which have a wide range of matrix 
substrates. Several of these enzymes (MMP1, 
MMP2, MMP8, MMP13 and MMP14) have 
activity against fibrillar collagen. Because few 
enzymes can cleave fibrillar collagen at neutral 
pH, regulation of this activity is thought to be 
a key step in the remodeling process in both 
health and disease. Proteoglycans are primarily 
degraded by enzymes of the ADAMTS family 
known as ‘aggrecanases’, which include 
ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8 
and ADAMTS9, although precisely which 
enzyme is involved in the turnover of tendon 
proteoglycan is currently unknown. The activity 
of metalloproteinases is highly regulated at 
multiple levels, including transcription, acti-
vation and inhibition by tissue inhibitors of 
metallo proteinase (TIMPs).22
Analysis of metalloproteinase gene expres-
sion in human Achilles tendon showed that 
almost all of the 23 MMP and 19 ADAMTS 
family members were detectable in normal 
tendon, although levels of expression varied 
widely.24 These enzymes are important in regu-
lating cell activity as well as matrix degradation, 
and they have roles in growth, development and 
repair, and also pathologic processes, including 
inflamma tion and degeneration.25 Evidence of 
their importance in tendon health is provided 
by the observation that broad-spectrum metallo-
proteinase inhibitors used in clinical trials 
caused a musculoskeletal syndrome similar 
to tendinopathy that resolved after treatment 
ended.26 Fluoroquinolone antibiotics, such as 
ciprofloxacin, can also induce tendinopathy in 
some patients, and these drugs can modulate 
MMP expression by tenocytes, at least in vitro.27 
Doxycycline, which inhibits several MMPs, 
significantly reduced the mechanical proper-
ties of healing tendons, demonstrating the 
importance of MMPs in tendon repair.28
MACROSCOPIC AND MICROSCOPIC 
OBSERVATIONS OF TENDINOPATHY
Tendons commonly affected by tendinopathy 
include the supraspinatus and long head of 
biceps in the shoulder, medial and lateral exten-
sors of the elbow, the patellar, the Achilles tendon 
and the posterior tibialis. In most cases, with 
the notable exception of the Achilles tendon, the 
site affected is at or near the insertion in a fibro-
cartilaginous region of the tendon.29 There are 
several common features of these sites: they 
are more highly stressed than other tendons, often 
exposed to repeated strains, including shear or 
compressive forces, and relatively less vascularized 
than the tendon midsubstance.
Histopathology of painful tendons shows 
changes in cellularity (both increased and 
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decreased), cell rounding, decreased matrix 
organization and increased infiltration of 
blood vessels.30 The abnormal vascularity has 
been associated with tendon pain.31 Ruptured 
tendons show similar degenerative features, 
although there is generally reduced cellularity 
and little evidence of neovascularization.32 The 
absence of new blood vessels and associated 
nerves might account for the absence of pain in 
‘spontaneous’ tendon ruptures, which have no 
preceding clinical symptoms. Most of the cells 
in tendinopathy specimens are fibroblast-like, 
albeit generally more rounded or ovoid, and 
few studies have identified inflammatory cells, 
at least in the tendon substance.30
MOLECULAR PATHOLOGY OF 
TENDINOPATHY
Biochemical and molecular studies of chronic 
tendinopathy during the past 15 years have 
increased our understanding of the underlying 
pathology; the main findings are summarized in 
Figure 2. In pathologic human tendon, there is 
increased expression of the messenger RNA of 
collagen types I and III, and increased amounts 
of type III collagen protein are found in the 
tendon matrix.33 The levels of fibronectin and 
tenascin C are also increased, consistent with a 
healing response.33 There is an increased level 
of glycosaminoglycan in the matrix33 and 
increased expression of the chondroitin sulfate 
proteoglycans, aggrecan and biglycan, even 
in the midsubstance of the Achilles tendon (in 
which fibrocartilage is not normally found), 
consistent with an adaptive response to shear or 
compression.34 Versican messenger RNA levels 
were unchanged in painful tendons, although 
there were changes in splicing of the gene that 
would affect the quantity of glycosaminoglycan 
attached to the mature protein.35
There are changes in the expression and activity 
of various metalloproteinases, and changes in 
the level of TIMPs that are consistent with increased 
proteolytic activity in degenerate tendons.33 
Pathologic (torn) rotator cuff tendons showed 
greatly increased collagen ase (MMP1) activity 
and reduced gelatinase (MMP2) and strome-
lysin (MMP3) activity compared with normal 
tendons; these changes correlated with levels of 
collagen turnover in the tissues.19 A study of gene 
expression in Achilles tendons showed that painful 
and ruptured tendons had distinct patterns of 
expression, consistent with quantitative and 
qualitative differences in catabolic activity in 
the different clinical entities.24 Ruptured 
tendons showed increased levels of expression 
of MMP1, MMP9, MMP19, MMP25 and TIMP1 
and decreased levels of expression of MMP3, 
MMP7, TIMP2, TIMP3 and TIMP4. Painful 
tendons showed reduced expression of MMP3, 
MMP10 and TIMP3 and increased expression 
of ADAM12 and MMP23. Little is known about 
the role and function of ADAM12 and MMP23 
in tendon, although both have been associated 
with changes in cell phenotype: ADAM12 with 
myo genesis and lipidogenesis, and MMP23 
with endo chondral ossification.36,37 In summary, 
the changes in the composition of tendon matrix 
are consistent with changes in cell-mediated 
matrix remodeling that precede the onset of clin-
ical symptoms, and these changes are mediated, at 
least in part, by metalloproteinase enzymes.
The cellular and molecular processes that 
drive the changes in the remodeling of tendon 
matrix in tendinopathy are yet to be determined. 
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Figure 2 Major structural and molecular changes in chronic tendinopathy. 
Typical features of tendinopathy are cell rounding and increased cell number, 
proteoglycan content and vascularity. Major molecular changes that have 
been identified by gene-expression studies, protein analysis or both 
are summarized. Molecules for which expression levels are increased are 
denoted by an upwards arrow, molecules for which expression levels 
are decreased are denoted by a downwards arrow and molecules for which 
expression levels remain unchanged are denoted by a horizontal arrow. Note 
that not all the changes shown have been rigorously confirmed, particularly 
at the protein level. Photomicrograph (A) is an alcian blue/H&E-stained 
section of supraspinatus tendinopathy, showing proteoglycans stained blue. 
Photomicrograph (B) is an H&E-stained section of Achilles tendinopathy, 
showing increased cellularity and proliferation of blood vessels. Abbreviations: 
ADAM, a disintegrin and metalloproteinase; ADAMTS, ADAM with 
thrombospondin motifs; AGE, advanced glycation end product; COX2, cyclo-
oxygenase 2; H&E, hemotoxylin and eosin; IGF-I, insulin-like growth factor 1; 
MMP, matrix metalloproteinase; NMDAR, N-methyl-D-aspartate receptor; 
PDGFR, platelet-derived growth factor receptor; PGE2, prostaglandin E2; 
TGF-β, transforming growth factor β; TGF-βR1, TGF-β type 1 receptor; 
VEGF, vascular endothelial growth factor.
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It is uncertain to what extent the remodeling 
represents a limited repair response to micro-
scopic fiber damage or an adaptive response 
to changes in cell-loading patterns. Excessive 
microstrain or ‘overuse’ acting on the tenocytes 
has been shown to elicit the expression of several 
inflammatory mediators and MMPs, at least 
in vitro, and it is suggested that this might trigger 
increased proteolytic activity in the tendon;38 
however, the levels of strain required to elicit 
this response are high, potentially much higher 
than the strains experienced by cells in vivo. 
More recently, it has been shown that rat teno-
cytes cultured in three-dimensional collagen 
gels will upregulate their expression of MMP13, 
the major rodent collagenase, if the gels become 
free floating and contract.39 These studies were 
extended to a study of stretched tendons in vitro, 
and it was shown that upregulation of MMP13 
occurred after failure of one or more of the fiber 
bundles.40 Thus, it seems that MMP output is 
attenuated by strain on the tendon cells through 
the cytoskeleton, and damage to tendon fibers 
results in the release of the cells from this strain 
regulation, resulting in increased collagenase 
activity and matrix degradation.
Although there is an absence of inflammatory 
cells in or around the lesion, this does not mean 
that inflammatory mediators are not implicated 
in tendinopathy, at least at some stage in the 
disease. Although levels of prostaglandin E2 were 
not significantly higher in the fluids surrounding 
painful tendons,41,42 levels of prostaglandin E2 
and several other inflammatory mediators, such 
as thromboxane, bradykinin and interleukin 
(IL)-6, are increased in peritendinous tissue 
after prolonged exercise.43–45 Other studies 
have reported increased levels of IL-1 in the 
tissues surrounding painful tendons, such as 
the bursa in the shoulder.46 Increased expression 
Table 1 Conservative treatments for chronic tendinopathy.a
Treatment Putative target or mode of action
Rest or modification of activity Removal of precipitating factors and prevention of reinjury
Orthotics (e.g. heal inserts) As above
Cryotherapy (e.g. ice packs and baths) Reduction of acute inflammation and decrease in cell metabolism
Heat treatment Stimulation of cell activity and increase in blood flow
Physiotherapy (including massage and 
controlled motion)
As above
Electrical stimulation Reduction of pain perception, stimulation of blood flow and increase in cell activity
Laser treatment (pulsed or continuous) Possible analgesic effects and unspecified (unknown) effects on cell activity
Pulsed electromagnetic fields As above
Ultrasound (0.75–3.0 MHz; pulsed or continuous) Thermal effects on tissue, stimulation of cell activity and increased blood flow
Extracorporeal shock-wave therapy As above, with possible stimulatory effects on neovascularization and inhibition 
of nociception
NSAIDs Reduction of inflammation through inhibition of prostaglandin synthesis
Corticosteroid injection (peritendinous) Reduction of inflammation and other unknown effects (generally inhibitory of 
protein synthesis)
Low-dose heparin Effect on tendon blood flow; possibly results in improved healing
Actovegin (deproteinized extract of calf’s blood) Unknown (suggested to promote glucose uptake and other effects on tendon cell 
metabolism that promote repair and resolution)
Glycosaminoglycan polysulfate Inhibition of inflammation, possibly also acting to inhibit metalloproteinase enzyme activity
Eccentric exercise therapy Thought to promote restoration of normal tissue structure, possibly through an effect on 
cell activity and matrix remodeling
Sclerosant injection (ultrasound-guided) Blocks tendon blood flow (targets neovascularization and associated nerve in-growth)
Platelet-rich plasma injection Contains growth factors (e.g. transforming growth factor β and platelet-derived growth 
factor) that promote matrix synthesis and tissue repair
aFew treatments for chronic tendinopathy are targeted against specific molecular processes. In most cases, there is little or no evidence of therapeutic effectiveness, 
especially in the long term. Large, appropriately controlled clinical trials with extended follow-up are required.
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of cyclo-oxygenase 2 was associated with patellar 
tendinopathy,47 and repeated injection of prosta-
glandin around the tendon has been shown to 
induce a degenera tive tendinopathy in animal 
models.48 The expression of growth factors 
and other potential modulators of tendon 
cell activity has been shown to increase in 
tendino pathy, including transforming growth 
factor β, platelet-derived growth factor receptor 
and neuro transmitters, such as glutamate and 
substance P.42,47,49–51 These changes might, 
however, be part of the healing response of the 
tissue and a requisite for tendon repair.52,53
NEW TREATMENTS FOR TENDINOPATHY 
AND FUTURE RESEARCH DIRECTIONS
A summary of current treatments and new thera-
pies in development is shown in Table 1. Exercise 
is important in both prevention and treatment 
of tendinopathy. Eccentric exercise therapy has 
been reported to have some effect in prospec-
tive, randomized trials in athletic patients;54,55 
however, a review of 20 published trials found 
that there was little evidence of a positive effect 
on clinical outcomes, such as reduction of pain, 
return to function and patient satisfaction.56 
Shock-wave therapy, which is thought to func-
tion on the tenocytes to stimulate repair, might be 
effective in a carefully selected group of patients,57 
although other studies have reported no signifi-
cant effect.58,59 Growth factors have been used 
for several years in an attempt to improve tendon 
healing, but there is currently no evidence that 
these are effective in tendinopathies. Nitric oxide, 
applied using topical nitroglycerin patches, has 
been shown to improve outcomes in randomized, 
double-blind, placebo-controlled trials, possibly 
by enhancing collagen synthesis.60–62 Sclerosant 
injections have been shown to give at least short-
term benefit,63 and might provide a rational 
basis for targeting neovascularization in painful 
tendinopathy, which might be triggered initially 
by hypoxia and regulated by levels of endostatin 
and vascular endothelial growth factor.64,65 
Aging might reduce the ability of tenocytes to 
remodel and repair lesions, supporting the use of 
stem-cell therapies that involve the injection 
of bone-marrow-derived cells into injured or 
degenerate tendon; this approach is currently 
being used to treat equine tendinopathy.66 Gene 
therapy to introduce specific anabolic or anti-
catabolic factors shows promise, and prepara-
tory studies have demonstrated the feasibility 
of this approach in animal tendons.67 Tissue 
engineering constructs are also being developed 
to repair or replace damaged tendons, although 
much more work is required before these 
constructs are used in humans.68
CONCLUSIONS
Future work is required to fully define the 
etiology of tendinopathy, including the develop-
ment and validation of both in vitro and in vivo 
models. In vitro models will enable the investi-
gation of the regulation of tenocyte activity by 
factors such as mechanical strain, cell–matrix 
interactions, cytokines, soluble factors, enzymes 
and signaling molecules. There are now several 
promising animal models,69,70 and further work 
using genome-wide screening and specific gene 
knockouts or transgenic animals should yield 
exciting new insights into the cause and progres-
sion of the disease. Metalloproteinases might be 
important in tendon pathology, but there are 
other classes of protease (e.g. cysteine, aspartate 
and serine proteases) that have, so far, received 
little attention. Because some enzyme activities 
are required in healthy and repairing tendon, 
it is essential to differentiate ‘good’ enzymes 
from those that are ‘bad’, so that drugs targeting 
specific activities can be developed for the 
treatment of tendinopathy.
KEY POINTS
■ Tendon disorders are common, often under-
reported and a major clinical problem
■ Most current treatments for tendinopathy are 
neither effective nor evidence-based
■ Molecular processes underlying tendinopathy 
are now being elucidated: metalloproteinase 
enzymes are thought to have a key role in 
the regulation of the activity of tendon cells 
and matrix remodeling in both normal and 
pathologic tendon
■ The potential roles of neuropeptides, 
inflammatory mediators and mechanical strain 
(either too much or too little) acting on the 
resident tenocytes are the source of some 
controversy and require in-depth investigation 
using in vitro and in vivo models
■ Excessive or inappropriate activity of 
destructive matrix-degrading enzymes might 
be a novel therapeutic target for tendinopathy; 
other treatments in development include the 
injection of stem cells, gene therapy and tissue 
engineering to repair or replace damaged 
tendon tissue
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